Sector News

UCB, Advent, Avista End Acquisition Agreement

December 17, 2014
Life sciences
Belgian pharmaceutical company UCB SA (UCB.BT), Advent International and Avista Capital Partners ended an acquisition agreement that would have seen Advent and Avista buy UCB’s U.S.-based speciality generics subsidiary for $ 1.5 billion, the company said in a press release.
 
UCB said it still plans to divest the generics unit, Kremers Urban Pharmaceutical Inc. It said the decision to terminate the acquisition agreement, which was signed last month, was a result of an “unexpected conflict” between the timing of the deal and a regulatory process launched in the U.S.
 
On Nov. 14, Kremers Urban said it had been informed by the U.S. Food and Drug Administration that the agency wanted an additional study on one of the company’s products–the methylphenidate hydrochloride extended-release (ER) tablet.
 
“While we are working on clarifying the situation around methylphenidate ER we will continue the divestiture process for Kremers Urban,” said Detlef Thielgen, Chief Financial Officer of UCB.
 
UCB said Tuesday’s announcement doesn’t impact the company’s most recent 2014 financial outlook, with the firm contining to expect total revenue of EUR3.15 billion-EUR3.25 billion ($3.94 billion-$4.07 billion) and underlying profits of EUR590 million to EUR620 million.
 
UCB’s shares closed 0.6% higher at EUR64.06.
 
By Laurence Norman
 
Source: Dow Jones Business News

Related News

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]